drugset / Trial / NCT04923126
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Phase 1/2
Recruiting
132 enrolled
St. Jude Children's Research Hospital
SpringWorks Therapeutics, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
Timeline
- Start
- 2021-06-21
- Primary completion
- 2031-06
- Completion
- 2031-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirdametinib | Small molecule | 3 mg/m2 | Oral |